查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950423

主動脈和周邊血管介入器械市場（按器械類型、技術、植入材料、應用和最終用戶分類），全球預測，2026-2032年

Aortic & Peripheral Vascular Interventional Devices Market by Device Type, Technology, Implant Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，主動脈和周邊血管介入器材市場價值將達到 87.8 億美元，到 2026 年將成長至 93.5 億美元，到 2032 年將達到 134.5 億美元，年複合成長率為 6.27%。

關鍵市場統計數據
基準年 2025 87.8億美元
預計年份：2026年 93.5億美元
預測年份 2032 134.5億美元
複合年成長率 (%) 6.27%

這是一份以臨床為依據、重點突出的概述，闡述了影響主動脈和周邊血管器械領域的程序優先事項、相關人員的壓力以及戰略要務。

主動脈和周邊介入器材市場已進入一個以快速臨床創新、不斷變化的手術環境以及對器械耐用性和長期療效日益嚴格的審查為特徵的階段。臨床醫師越來越重視那些既易於實施又能針對特異性病變改善療效的技術，而醫療系統則要求在手術全期資源利用率和患者吞吐量方面取得顯著改善。同時，監管路徑和報銷動態也在同步發展，影響企業如何優先考慮研發、上市後證據的收集以及市場准入順序。

臨床創新、材料科學進步、手術流程向門診轉移以及供應鏈重組，正在如何重塑血管器械生態系統的策略重點？

近年來，主動脈和周邊血管介入治療領域發生了一系列變革性變化，重新定義了競爭優勢，而且這些變化仍在加速發展。首先，臨床實踐正朝著微創技術和先進的血管內介入方法發展，從而縮短了住院時間，並擴大了傳統上只能接受保守治療的患者範圍。器械小型化和輸送系統的改進減少了手術創傷，使得門診和混合手術成為可能，隨著手術方式的轉變，也創造了商業性機會。

評估2025年關稅對經濟、供應鏈和臨床的多層次影響，並考慮相關人員如何積極應對。

2025年宣布的一系列關稅措施的累積影響，給主動脈和周邊血管護理領域的製造商、醫療服務提供者和採購機構帶來了複雜的挑戰。進口原料和成品器械關稅的增加，直接推高了依賴全球孤立供應鏈的製造商的投入成本。這些壓力迫使多家公司重新評估其定價策略，盡可能承擔成本以維持市場成長勢頭，並加快供應鏈的長期調整以降低未來風險。

制定有針對性的產品和商業策略，採用以細分市場主導的詳細觀點，將應用、設備設計、技術、材料科學和最終用戶畫像連結起來。

細分市場分析能夠深入了解主動脈和周邊血管器械市場中臨床需求與技術創新之間的交集。在考慮應用場景時，主動脈和周邊應用場景的差異決定了器械的尺寸、輸送系統機制和手術流程，進而影響臨床訓練需求和設備需求。按器械類型分類，市場涵蓋：切割球囊（包括切割球囊、藥物釋放型血管成形術用氣球和標準球囊）；栓塞保護裝置（按遠端保護和近端保護區分）；用於腹主動脈和胸主動脈的血管內血管支架；球囊擴張式或自擴張式外周支架；以及血栓除去裝置（包括機械血栓切除術和抽血栓切除術）。這些器械層面的差異驅動著醫院和門診的研發重點、監管證據的累積以及庫存策略。

美洲、歐洲、中東和非洲以及亞太地區的區域管理體制、報銷模式和手術流程採用模式將如何決定差異化的商業化和生產選擇？

區域趨勢正在影響主動脈和周邊血管領域的創新發展、監管策略和商業性執行。在美洲，臨床應用往往受到獎勵手術效率和療效的報銷機制的驅動，這為那些能夠縮短住院時間和提高長期通暢性的技術創造了有利環境。這一趨勢促使製造商投資於可靠的臨床證據，並儘早與大規模綜合醫療網路合作，以獲得優先供應商地位和基於銷售的合約。

主導情報的競爭態勢評估、創新方向以及決定醫療器材平台和臨床細分市場市場領導地位的策略行動

主動脈和周邊血管器材領域的競爭格局由全球平台領導者、專業創新者和垂直整合型競爭對手組成，它們在設計、材料和臨床證據方面競爭。擁有豐富產品系列的老字型大小企業利用規模經濟優勢，為長期臨床試驗提供資金籌措，並維持多元化的製造地，從而提供吸引大型醫療系統和集團採購組織的端到端外科解決方案。專業公司則專注於特定器械領域，例如藥物釋放型球囊、先進的血管支架設計和改良的血栓切除系統。在這些領域，臨床差異化和針對性的證據推動了關鍵意見領袖（KOL）對產品的快速接受。

製造商和供應商應採取實際有效、影響深遠的策略行動和商業性轉型，以確保韌性、加速產品普及並展現長期價值。

行業領導者必須採取一系列戰術性和策略舉措，以維持成長並應對快速變化的臨床和商業環境。製造商應優先進行產品組合最佳化，專注於高影響力醫療器材子集，並選擇性地投資於能夠帶來可衡量臨床優勢的藥物塗層和材料科學升級。同時，透過對多家供應商進行資格認證、尋求近岸生產方案以及發展模組化生產能力來加強供應鏈多元化，可以降低貿易中斷和關稅波動帶來的風險。

該分析基於嚴格的混合方法研究方法，結合了主要臨床訪談、次要證據綜合、分割映射和檢驗程序。

本執行摘要的研究採用了系統性的一手和二手調查方法相結合的方式，以確保其可靠性和相關性。一手研究包括對介入性心臟病專家、血管外科醫生、採購主管和醫療設備工程師進行結構化訪談，以收集關於臨床效用、器械選擇標準和運營限制的第一手資訊。此外，還與器材創新者和醫療系統領導者舉行了諮詢小組簡報會，檢驗新出現的主題並測試商業場景。

簡潔地概括了關鍵的臨床、商業性和營運問題，為相關人員應對不斷變化的挑戰提供協作方向，並確保患者照護的永續進步。

總而言之，主動脈和周邊介入器材市場格局正受到多種因素的重塑，包括：臨床上對微創和持久治療方法的偏好；材料和藥物輸送技術的創新正在改變再次介入的風險狀況；以及商業性模式向基於價值的採購和具有韌性的供應鏈轉變。這些因素相互作用，影響所有器械類型，從血管成形球囊和栓塞保護系統到複雜的血管支架和血栓切除平台，並且會因技術、植入材料和最終用戶環境的不同而有所差異。因此，技術差異化必須與可證明的營運和經濟價值結合，才能確保器械的持續應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 主動脈及周邊血管介入器材市場（依器械類型分類）

  • 血管成形球囊
    • 切割球囊
    • 藥物釋放型球囊
    • 標準氣球
  • 栓塞保護裝置
    • 遠端保護
    • 近端保護
  • 血管內支架血管支架
    • 腹主動脈
    • 胸主動脈
  • 周邊血管支架
    • 氣球膨脹類型
    • 自膨脹
  • 血栓清除裝置
    • 機械血栓切除術
    • 抽吸血栓清除法

9. 主動脈及周邊介入器材市場（依技術分類）

  • 裸金屬
  • 藥物包衣型

10. 主動脈及周邊血管介入器材市場（依植入材料分類）

  • 鈷鉻
  • 鎳鈦諾
  • 不銹鋼

11. 主動脈及周邊血管介入器材市場（依應用領域分類）

  • 主動脈
  • 外圍

12. 主動脈和周邊血管介入器材市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

13. 各地區主動脈及周邊血管介入器材市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 主動脈和周邊介入器材市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國主動脈及周邊血管介入器材市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國主動脈及周邊介入器材市場

17. 中國：主動脈與周邊血管介入器材市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health
  • Cook Medical LLC
  • Getinge AB
  • Johnson & Johnson
  • LivaNova PLC
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Endovascular MedTech
  • Penumbra, Inc.
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD855

The Aortic & Peripheral Vascular Interventional Devices Market was valued at USD 8.78 billion in 2025 and is projected to grow to USD 9.35 billion in 2026, with a CAGR of 6.27%, reaching USD 13.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.78 billion
Estimated Year [2026] USD 9.35 billion
Forecast Year [2032] USD 13.45 billion
CAGR (%) 6.27%

A focused, clinically grounded overview that situates procedural priorities, stakeholder pressures, and strategic imperatives shaping the aortic and peripheral vascular device arena

The aortic and peripheral vascular interventional device landscape has entered a period defined by rapid clinical innovation, shifting procedural settings, and heightened scrutiny on device durability and long-term outcomes. Clinicians increasingly prioritize technologies that combine ease of delivery with improved lesion-specific performance, while health systems demand demonstrable improvements in perioperative resource utilization and patient throughput. At the same time, regulatory pathways and reimbursement dynamics are evolving in parallel, shaping how companies prioritize development, post-market evidence generation, and market entry sequencing.

This executive summary synthesizes contemporary clinical trends, competitive behaviors, and strategic imperatives facing manufacturers, providers, and purchasers. It highlights how therapy selection for aortic compared with peripheral applications is being influenced by device design, material science, and adjunctive technologies. The summary also frames why decisions by hospitals, ambulatory surgery centers, and specialty clinics now extend beyond clinical efficacy to include procedural efficiency, inventory management, and lifecycle costs. By situating clinical drivers alongside commercial and regulatory realities, the introduction sets the foundation for deeper analysis and actionable recommendations contained in the subsequent sections.

How clinical innovation, material science advances, procedural migration to outpatient settings, and supply chain reconfiguration are reshaping strategic priorities across the vascular device ecosystem

Over recent years, multiple transformative shifts have redefined competitive advantage in aortic and peripheral vascular interventions, and these shifts continue to accelerate. First, the clinical community is converging on less invasive techniques and refined endovascular approaches that reduce length of stay and broaden candidacy among patients previously managed conservatively. Device miniaturization and delivery-system refinement have decreased access trauma and facilitated treatment in outpatient and hybrid settings, creating commercial opportunities tied to procedural migration.

Second, material innovation has become a decisive differentiator. Adoption of nitinol for its superelastic properties, cobalt chromium for radial strength, and stainless steel for cost-effective scaffolding has allowed manufacturers to tailor performance across aortic and peripheral indications. Concurrently, drug-coating technologies are influencing restenosis management strategies, fostering new combinations of scaffold design and pharmacologic control that change follow-up pathways and reintervention rates. Third, the integration of digital imaging, procedural guidance systems, and real-time analytics is improving device placement accuracy and reducing operator variability, while creating data-rich evidence streams for payers and regulators.

Fourth, the commercial environment has shifted toward outcome- and value-based contracting models. Payers and large hospital systems increasingly seek devices and care pathways that demonstrably lower total cost of care across episodes, incentivizing manufacturers to demonstrate longitudinal benefits. Finally, supply chain resilience and regional manufacturing strategies have emerged as strategic priorities following episodic disruptions, driving investments in dual-sourcing, inventory optimization, and near-shoring. Together, these shifts are reshaping R&D priorities, go-to-market strategies, and partnership models across the ecosystem.

Assessing the layered economic, supply chain, and clinical adoption consequences that followed tariff measures introduced in 2025 and how stakeholders can respond proactively

The cumulative impact of tariff actions announced in 2025 has created complex headwinds for manufacturers, providers, and procurement organizations engaged in aortic and peripheral vascular therapies. Tariff-induced cost escalation for imported raw materials and finished devices has directly increased input costs for manufacturers that rely on globalized supply chains. These pressures have compelled several companies to reassess pricing strategies, absorb costs where possible to protect adoption momentum, and accelerate longer-term supply chain adjustments to mitigate future exposure.

Beyond immediate cost implications, tariffs have influenced strategic decisions related to manufacturing footprint and supplier selection. Companies with flexible manufacturing models and multi-jurisdictional production have been better positioned to shield end users from acute price shocks. In contrast, single-source supply models and heavy dependence on components produced in tariff-affected jurisdictions have necessitated rapid supplier diversification or investments in alternative materials and processes. For hospitals and ambulatory surgery centers, the cumulative effect has been constrained purchasing flexibility and an increased emphasis on product rationalization to manage capital expenditure and inventory carrying costs.

Tariffs have also indirectly affected clinical adoption patterns. Where increased costs have coincided with marginal clinical advantage between competing technologies, procurement committees have favored cost-stable alternatives or deferred elective procedures. Conversely, technologies that reduce lengths of stay, reintervention, or downstream resource utilization have preserved purchasing preference despite higher upfront pricing, as their value proposition aligns with institutional cost-containment goals. Finally, policy uncertainty created by tariff shifts has amplified the need for scenario-based planning across commercial, clinical, and regulatory functions, encouraging stakeholders to model multiple procurement and reimbursement outcomes and to prioritize contractual flexibility and supply chain visibility.

A detailed segmentation-driven perspective that connects application, device design, technology, material science, and end-user profiles to inform targeted product and commercial strategies

Segmentation drives a nuanced understanding of where clinical demand and innovation converge within the aortic and peripheral vascular device landscape. When considering application, differentiation between aortic and peripheral use cases dictates device sizing, delivery-system mechanics, and procedural workflows, which in turn influence clinical training requirements and capital equipment needs. Within device type, the market spans angioplasty balloons-including cutting balloons, drug-coated balloons, and standard balloons-embolic protection devices differentiated by distal or proximal protection, endovascular stent grafts classified into abdominal aortic and thoracic aortic categories, peripheral vascular stents offered as balloon-expandable or self-expanding options, and thrombectomy devices that encompass mechanical and suction thrombectomy approaches. These device-level distinctions drive R&D priorities, regulatory evidence portfolios, and inventory strategies for hospitals and ambulatory settings.

Technology segmentation between bare metal and drug-coated devices further influences clinical pathways and follow-up regimens, as drug-coated platforms aim to reduce restenosis risk and alter reintervention calculus. Implant material choices-cobalt chromium, nitinol, and stainless steel-create performance trade-offs around radial strength, conformability, fatigue resistance, and cost, thereby guiding surgeon selection by lesion type and anatomical demands. End-user segmentation across ambulatory surgery centers, hospitals, and specialty clinics determines procurement cycles, stocking practices, and acceptable device complexity; ambulatory settings typically favor shorter procedure times and simplified inventories, hospitals accommodate more complex cases and higher device diversity, and specialty clinics concentrate on niche procedural volumes and relationship-based purchasing. Mapping strategy to these segmentation axes enables companies and providers to prioritize product portfolios, clinical evidence generation, and commercial models in ways that align with the procedural mix and operational constraints of target end users.

How regional regulatory regimes, reimbursement models, and procedural adoption patterns across the Americas, EMEA, and Asia-Pacific dictate differentiated commercialization and manufacturing choices

Regional dynamics shape innovation pipelines, regulatory strategies, and commercial execution across the aortic and peripheral vascular landscape. In the Americas, clinical adoption is often driven by reimbursement structures that reward procedural efficiency and outcomes, creating a strong environment for technologies that demonstrate reduced length of stay and improved long-term patency. This dynamic encourages manufacturers to invest in robust clinical evidence and to engage early with large integrated delivery networks to secure preferred-supplier status and volume-based arrangements.

Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement environment where national health technology assessment processes and procurement consortia frequently influence device pricing and uptake. Manufacturers operating across this region must adapt to varying evidence requirements and local procurement cycles, while leveraging centralized clinical data to meet diverse national expectations. In contrast, Asia-Pacific is characterized by rapid procedural volume growth, divergent regulatory timelines, and increasing local manufacturing capacity. Market entrants that balance global clinical standards with locally relevant value propositions-including cost-effective implant materials and simplified delivery systems-are often better positioned to scale in high-volume centers while building partnerships with regional distributors and health systems.

Across all regions, cross-border trade policies, reimbursement reform, and the pace of outpatient procedural adoption will continue to shape where and how new devices are launched. Manufacturers should therefore adopt differentiated regional strategies that align clinical evidence packages, pricing models, and supply chain structures with the unique regulatory and provider landscapes of each geography.

An intelligence-driven appraisal of competitive dynamics, innovation vectors, and strategic behaviors that are defining market leadership across device platforms and clinical niches

The competitive landscape in aortic and peripheral vascular devices is marked by a mix of global platform leaders, specialized innovators, and vertically integrated rivals that compete across design, materials, and clinical evidence. Established companies with broad portfolios leverage scale to fund longitudinal clinical trials and to maintain diverse manufacturing footprints, enabling them to offer end-to-end procedural solutions that appeal to large health systems and group purchasing organizations. Specialized companies focus on niche device types-such as drug-coated balloons, advanced stent graft architectures, or thrombectomy system refinements-where clinical differentiation and targeted evidence can accelerate adoption among key opinion leaders.

Strategic behaviors shaping the competitive field include acquisition of complementary technologies to fill gaps in product portfolios, co-development agreements with imaging and guidance system providers to enhance procedural accuracy, and investments in manufacturing capabilities to reduce exposure to tariff and logistics risk. In addition, many market participants are expanding services around device offerings, including training programs, procedural analytics, and warranty or outcome-based contracting mechanisms to strengthen customer relationships. Competitive advantage increasingly arises from the ability to couple compelling device performance with demonstrable operational benefits for providers, backed by high-quality real-world evidence and collaborative commercial models that reduce procurement friction.

Practical, high-impact strategic actions and commercial pivots that manufacturers and providers should implement to secure resilience, accelerate adoption, and demonstrate long-term value

Industry leaders must adopt a suite of tactical and strategic initiatives to sustain growth and respond to a rapidly evolving clinical and commercial environment. Manufacturers should prioritize portfolio rationalization focused on high-impact device families and invest selectively in drug-coating and material science upgrades that offer measurable clinical advantages. Concurrently, strengthening supply chain diversification by qualifying multiple suppliers, pursuing near-shore manufacturing options, and developing modular production capabilities can reduce exposure to trade disruptions and tariff fluctuations.

Commercially, value-based contracting and outcome-linked pricing models merit greater emphasis, with manufacturers developing the capability to present longitudinal clinical and economic evidence that resonates with hospital decision-makers and payers. Investing in data capture and analytics around procedural outcomes will support those contractual conversations and enable continuous performance improvement. Clinician education and streamlined training pathways are also essential; manufacturers should collaborate with leading clinicians to shorten learning curves for newer delivery systems and to codify best practices that improve consistency of outcomes.

Finally, companies should accelerate partnerships with imaging and digital procedural guidance providers to enhance device placement accuracy and to create integrated solutions that improve the overall procedural experience. For providers, adopting inventory rationalization strategies aligned to procedural mix and establishing preferred supplier relationships based on total cost of care metrics will reduce variability and control expenditure. Taken together, these actions will enhance resilience, support adoption of differentiated technologies, and align commercial approaches with evolving stakeholder expectations.

A rigorous mixed-methods research approach combining primary clinical interviews, secondary evidence synthesis, segmentation mapping, and validation procedures to underpin the analysis

The research behind this executive summary relied on a systematic blend of primary and secondary intelligence methodologies to ensure robustness and relevance. Primary research included structured interviews with interventional cardiologists, vascular surgeons, procurement directors, and device engineers to capture firsthand perspectives on clinical utility, device selection criteria, and operational constraints. These interviews were complemented by advisory-panel briefings with device innovators and health system leaders to validate emerging themes and to test commercial scenarios.

Secondary research synthesized peer-reviewed clinical literature, regulatory filings, device labeling, and public financial disclosures to map product attributes, material choices, and approval trajectories. Data triangulation combined qualitative insights with device-specific technical parameters and policy developments, enabling cross-validation of findings and identification of consensus trends. Segmentation mapping was applied to organize insights across application (aortic versus peripheral), device type and subtypes including angioplasty balloons, embolic protection devices, endovascular stent grafts, peripheral stents, and thrombectomy systems, technology differentiation between bare metal and drug-coated platforms, implant materials such as cobalt chromium, nitinol, and stainless steel, and end-user settings spanning ambulatory surgery centers, hospitals, and specialty clinics.

Quality controls included validation of key assertions through multiple independent sources, sensitivity checks on strategic conclusions, and peer review by clinical advisors. Limitations of the methodology were made explicit, particularly where emerging technologies lacked long-term clinical follow-up or where regional regulatory variability constrained direct comparability. Where appropriate, scenario analysis was used to present alternative outcomes rather than single-point predictions, ensuring that stakeholders can apply the research within their own risk and investment frameworks.

A concise synthesis of clinical, commercial, and operational imperatives that stakeholders must align on to navigate dynamic challenges and secure sustainable advances in patient care

In summary, the aortic and peripheral vascular interventional device environment is being redefined by clinical preferences for less invasive, more durable therapies; by material and drug-delivery innovations that alter reintervention risk profiles; and by commercial shifts toward value-based procurement and resilient supply chains. These forces interact across device types-from angioplasty balloons and embolic protection systems to complex stent grafts and thrombectomy platforms-and vary by technology, implant material, and end-user setting. The result is a landscape where technical differentiation must be paired with demonstrable operational and economic value to secure durable adoption.

Stakeholders who align product development with clear clinical endpoints, who invest in supply chain robustness, and who embrace outcome-linked commercial models will be best positioned to capture long-term value. Regulators and payers will continue to place a premium on high-quality evidence and real-world performance data, making longitudinal outcome measurement a central component of successful market entry. By integrating clinical, commercial, and operational strategies, manufacturers and providers can navigate tariff volatility, regional variation, and evolving procedural practice to deliver improved patient outcomes while managing institutional cost pressures.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic & Peripheral Vascular Interventional Devices Market, by Device Type

  • 8.1. Angioplasty Balloons
    • 8.1.1. Cutting Balloons
    • 8.1.2. Drug-Coated Balloons
    • 8.1.3. Standard Balloons
  • 8.2. Embolic Protection Devices
    • 8.2.1. Distal Protection
    • 8.2.2. Proximal Protection
  • 8.3. Endovascular Stent Grafts
    • 8.3.1. Abdominal Aortic
    • 8.3.2. Thoracic Aortic
  • 8.4. Peripheral Vascular Stents
    • 8.4.1. Balloon-Expandable
    • 8.4.2. Self-Expanding
  • 8.5. Thrombectomy Devices
    • 8.5.1. Mechanical Thrombectomy
    • 8.5.2. Suction Thrombectomy

9. Aortic & Peripheral Vascular Interventional Devices Market, by Technology

  • 9.1. Bare Metal
  • 9.2. Drug-Coated

10. Aortic & Peripheral Vascular Interventional Devices Market, by Implant Material

  • 10.1. Cobalt Chromium
  • 10.2. Nitinol
  • 10.3. Stainless Steel

11. Aortic & Peripheral Vascular Interventional Devices Market, by Application

  • 11.1. Aortic
  • 11.2. Peripheral

12. Aortic & Peripheral Vascular Interventional Devices Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Aortic & Peripheral Vascular Interventional Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Aortic & Peripheral Vascular Interventional Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Aortic & Peripheral Vascular Interventional Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Aortic & Peripheral Vascular Interventional Devices Market

17. China Aortic & Peripheral Vascular Interventional Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Cardinal Health
  • 18.10. Cook Medical LLC
  • 18.11. Getinge AB
  • 18.12. Johnson & Johnson
  • 18.13. LivaNova PLC
  • 18.14. Medtronic plc
  • 18.15. Merit Medical Systems, Inc.
  • 18.16. MicroPort Endovascular MedTech
  • 18.17. Penumbra, Inc.
  • 18.18. Terumo Corporation
  • 18.19. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL AORTIC & PERIPHERAL VASCULAR INTER